BMJ Visual Summary

FDA allows drugs without proven clinical benefit to languish for years on accelerated pathway

By Elisabeth Mahase

Taken Directly from the BMJ doi:

Criticisms of the US Food and Drug Administration’s accelerated approval process have resurfaced after the recent approval of aducanumab (Aduhelm) for dementia. Elisabeth Mahase finds that the process is plagued by missing efficacy data and questionable evidence.

Read the full article here:


FDA calls for investigation into industry influence during Alzheimer’s drug approval Published: 12 July 2021; BMJ 374 doi:10.1136/bmj.n1778
FDA approves controversial Alzheimer’s drug despite uncertainty over effectiveness Published: 08 June 2021; BMJ 373 doi:10.1136/bmj.n1462